ALKS

As of 2026-09-11, ALKS scores 46out of 100 on QNTM’s five-factor quantitative model, a moderate conviction reading. The score blends momentum, quality, volume, value and sentiment, then adjusts for the current macro regime. ALKS trades at $45.97, 22% above the band ceiling.

ALKS scores 46 out of 100 on QNTM's five-factor model — a moderate reading — neither strongly favored nor flagged for weakness at 46. Its strongest factor is value at 58 (solid), where it screens cheap on the model's valuation inputs, followed by momentum at 55. The weakest is sentiment at 30, where sentiment signals are working against it. Among Healthcare stocks it ranks in roughly the top 41% of the Healthcare names the model scores.

On valuation, ALKS is priced near the top of its recent range — the rich end on the model's valuation read. The blended composite before the macro overlay was 48. Same-sector names the model rates nearby include HALO, THC, HNGE.

This is a descriptive factor read on ALKS, recomputed each trading day and shown with its reasoning — not a recommendation to buy, hold or sell. The score reflects where ALKS sits on the model's measures today, and can change as new data arrives.

FACTOR BREAKDOWN

VALUATION RANGE

QNTM’s descriptive fair-value band for ALKS runs $24.06–$37.53. Current price $45.97 sits 22% above the band ceiling. This is valuation context, not a price target.

OTHER HEALTHCARE NAMES

QNTM provides quantitative model outputs for informational and educational purposes only. It is not investment advice and QNTM is not a registered investment adviser. Scores are rankings, not buy/sell recommendations. Data as of 2026-09-11.